OSRH OSR Health, Inc.
Listings ·
OSR Health, whose shares have traded over the counter since Nasdaq suspended them on August 26, 2026, says it will update shareholders by November 6, 2026 on how it plans to regain a listing.
Under an amended license with BCM Europe AG, OSR Health can elect to take up to $15,000,000 of convertible notes in place of an equity purchase option.
Dr. Constance Hoefer gave notice on September 30, 2026, and her resignation took effect at once, the company reported in an 8-K filed October 2.
The Nasdaq Hearings Panel scheduled OSR Health's hearing for September 29, 2026, while trading in its securities remains suspended under the company's own filing.
Nasdaq staff said OSR Health did not regain compliance with the $1.00 minimum bid price, and trading in its common stock and warrants will be suspended on August 26, 2026.
The company said a July 31 statement should not be read as Nasdaq approval of the Shareholder Loyalty CVR Program, and the August 14, 2026 record date is unchanged.
In a verbal communication, Nasdaq said the Shareholder Loyalty CVR program will not trigger a mechanical price adjustment, OSR Health said on July 31, 2026.
The board postponed the annual stockholder meeting that had been scheduled for June 18, 2026, and said it has not yet set a new date.
The $30,000,000 price is due in full on completion of a Phase 2 study of VXM01, and the company may make voluntary partial payments before then.
BCM Europe, the company's largest shareholder, holds an exclusive global license and has pledged its entire stake as collateral for milestone payments of up to $815 million.
The company has until March 4, 2026 to regain compliance with the minimum bid price rule. Its shares keep trading on The Nasdaq Capital Market for now.
The company blamed a delay in finalizing its statements with its auditors after its February 14, 2025 business combination.
Bellevue's note to its merger partner bears interest at 3.96% a year and is due on October 25, 2025. Bellevue's chief executive is also chairman of OSR Holdings.
OSR Health, Inc. describes itself as a global healthcare holding company with operations in South Korea and Switzerland and an office in the United States. It says it identifies, leads and supports subsidiaries built around pharmaceutical or medical device technologies, and it expects to attract industry partners as co-investors or through technology licensing deals. Its subsidiaries are engaged in distinct areas of therapeutics research, including oral T-cell immunotherapies and recombinant biologics. The subsidiary Vaximm is developing oral T-cell immunotherapies for disorders that require the targeted elimination of specific cell populations, such as neoplasms, other proliferative diseases and chronic infections. A second subsidiary is developing a design-augmented recombinant biologic for bone and cartilage regeneration. A third subsidiary works in neurovascular surgical devices. The company says its subsidiaries hold 10 patent families of issued patents and pending applications, with anticipated expiration between 2032 to 2041.
| Product or program | What it is | Stage |
|---|---|---|
| VXM01 DNA vaccine | DNA vaccine for use in pancreatic cancer patients, Vaximm patent family | |
| VXM04-MSLN | MSLN targeting DNA vaccine for cancer immunotherapy, Vaximm patent family | |
| Darnatein | Designer ligands of the TGF-beta superfamily under exclusive license |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.9 million | $3.5 million |
| Research and development | $318,446 | $161,155 |
| Net income (loss) | -$2.4 million | |
| Cash from operations | -$4.3 million | -$1.8 million |
| Cash and equivalents | $1.7 million | $341,543 |
Our latest story on this, dated Oct 28, 2026: "Nasdaq panel delists OSR Health over $1.00 bid price rule". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 15, 2026: "OSR Health amends VXM01 license to allow up to $15,000,000 in convertible notes". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 9, 2025: "OSR Holdings (now OSR Health) gets Nasdaq notice after 30 days below $1.00". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 27, 2026: "OSR Health agrees to buy VXM01 assets from Vaximm for $30,000,000". The story links the filing or release it is based on. Read the story.
OSR Health, Inc. trades under the ticker OSRH on OTC.
OSR Health, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for OSR Health, Inc. is 1840425. Its filings are on SEC EDGAR.
35,118,692 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Our directory records OSR Health, Inc. under United States.
Our directory classifies OSR Health, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for OSR Health, Inc. is US68840D1028.
aibio.space lists OSR Health, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
OSR Health, Inc. describes itself as a global healthcare holding company with operations in South Korea and Switzerland and an office in the United States. It says it identifies, leads and supports subsidiaries built around pharmaceutical or medical device technologies, and it expects to attract industry partners as co-investors or through technology licensing deals.
VXM01 DNA vaccine: DNA vaccine for use in pancreatic cancer patients, Vaximm patent family Stage: Not stated in text.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio